FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251686875> ?p ?o ?g. }

• W4251686875 endingPage "4932" @default.
• W4251686875 startingPage "4932" @default.
• W4251686875 abstract "Abstract Background: Oxaliplatin confers tumoricidal effect by forming platinum-DNA adducts and is an integral part of the treatment paradigm for patients with colorectal cancer (CRC). The nucleotide excision repair pathway (NERP) plays a crucial role in tissue resistance to the drug. We have previously demonstrated that ERCC1 (part of NERP) is an inducible gene in CRC cell lines on exposure to oxaliplatin, and high levels confer drug resistance. We aimed to translate these findings by using Peripheral Blood Mononuclear Cells (PBMC) as a surrogate and assess ERCC1 as a biomarker of sensitivity to oxaliplatin therapy. Additionally, we assessed prevalence of single nucleotide polymorphisms (SNP) and its relation to patient outcomes. Methods: In consenting patients with CRC who received oxaliplatin, blood was sampled at 0, 2, 48 hours, and 14 days during any cycle of chemotherapy, and/or DNA from formalin fixed paraffin embedded (FFPE) tissue was isolated. ERCC1 gene expression was quantified by qPCR (quantitative real time polymerase chain reaction) and WB (western blotting). SNPs were analyzed through Sanger sequencing of DNA from blood or tissue. Clinical benefit from oxaliplatin was determined using the parameters of relapse free survival (RFS) for limited stage and progression free survival (PFS) for mCRC. Results: 54 patients had serial blood sampled; 25 (46.3%) had mCRC and 1 was excluded due to mortality prior to therapy. 13 (52%) had an increase in ERCC1 expression from baseline, while 11 (48%) showed no change or decrease. Median PFS was 190 and 237 days respectively (log-rank test HR 2.35, CI 1.005-5.479; p = 0.0182). In the 29 patients with limited stage disease, 19 (65.5%) had an induction of ERCC. In these patients change in expression did not correlate with RFS. We did not find any significant correlation of PFS with baseline expression of ERCC1 in either group. SNP in rs11615 (AAT&gt;AAC, 97 samples) was assessed. 80/97 had stage 4 disease, with AAC in 69 (86.3%) patients. Median PFS was lower in patients with AAC than AAT (203 vs 684.5 days; log-rank test HR 2.4, CI 1.45-3.97, p=0.0045). On analysis of racial distribution, blacks had the highest prevalence of AAC (100%), followed by Hispanics (81.8%), persons of mixed race (76.9%) and whites (68.8%) (Fisher exact test p=0.0004). Conclusions: We confirm our hypothesis that the ERCC1 gene is induced in vivo in a sub-population of patients on treatment with oxaliplatin. This induction can serve as a potential marker of drug-resistance in mCRC as evidenced by the significant difference in PFS. Additionally, presence of SNP is an independent marker of drug resistance, which has a significant pattern of distribution among various races. Analysis of a second SNP (rs3212986), also implicated in drug resistance, is underway. Citation Format: Devika Rao, Atrayee Basu Mallick, Titto Augustine, Cecilia Daroqui, Jeeshan Jiffry, Amartej Merla, Imran Chaudhary, Raviraja Seetharaman, Arjun Sood, Srikanth Gajavelli, Santiago Aparo, Lakshmi Rajdev, Andreas Kaubisch, Jennifer Chuy, Radhashree Maitra, Sanjay Goel. Excision repair cross-complementing group-1 (ERCC1) induction and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4932." @default.
• W4251686875 created "2022-05-12" @default.
• W4251686875 creator A5001637416 @default.
• W4251686875 creator A5008973274 @default.
• W4251686875 creator A5011233983 @default.
• W4251686875 creator A5014248517 @default.
• W4251686875 creator A5025610895 @default.
• W4251686875 creator A5029455802 @default.
• W4251686875 creator A5045850122 @default.
• W4251686875 creator A5046669683 @default.
• W4251686875 creator A5048225764 @default.
• W4251686875 creator A5062273071 @default.
• W4251686875 creator A5066809157 @default.
• W4251686875 creator A5069675476 @default.
• W4251686875 creator A5073149970 @default.
• W4251686875 creator A5073337703 @default.
• W4251686875 creator A5073988836 @default.
• W4251686875 creator A5081297141 @default.
• W4251686875 date "2019-07-01" @default.
• W4251686875 modified "2023-09-27" @default.
• W4251686875 title "Abstract 4932: Excision repair cross-complementing group-1 (ERCC1) induction and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin" @default.
• W4251686875 doi "https://doi.org/10.1158/1538-7445.am2019-4932" @default.
• W4251686875 hasPublicationYear "2019" @default.
• W4251686875 type Work @default.
• W4251686875 citedByCount "0" @default.
• W4251686875 crossrefType "journal-article" @default.
• W4251686875 hasAuthorship W4251686875A5001637416 @default.
• W4251686875 hasAuthorship W4251686875A5008973274 @default.
• W4251686875 hasAuthorship W4251686875A5011233983 @default.
• W4251686875 hasAuthorship W4251686875A5014248517 @default.
• W4251686875 hasAuthorship W4251686875A5025610895 @default.
• W4251686875 hasAuthorship W4251686875A5029455802 @default.
• W4251686875 hasAuthorship W4251686875A5045850122 @default.
• W4251686875 hasAuthorship W4251686875A5046669683 @default.
• W4251686875 hasAuthorship W4251686875A5048225764 @default.
• W4251686875 hasAuthorship W4251686875A5062273071 @default.
• W4251686875 hasAuthorship W4251686875A5066809157 @default.
• W4251686875 hasAuthorship W4251686875A5069675476 @default.
• W4251686875 hasAuthorship W4251686875A5073149970 @default.
• W4251686875 hasAuthorship W4251686875A5073337703 @default.
• W4251686875 hasAuthorship W4251686875A5073988836 @default.
• W4251686875 hasAuthorship W4251686875A5081297141 @default.
• W4251686875 hasConcept C104317684 @default.
• W4251686875 hasConcept C104451858 @default.
• W4251686875 hasConcept C121608353 @default.
• W4251686875 hasConcept C126322002 @default.
• W4251686875 hasConcept C134935766 @default.
• W4251686875 hasConcept C135763542 @default.
• W4251686875 hasConcept C143998085 @default.
• W4251686875 hasConcept C153209595 @default.
• W4251686875 hasConcept C2776694085 @default.
• W4251686875 hasConcept C2778239845 @default.
• W4251686875 hasConcept C2779309665 @default.
• W4251686875 hasConcept C2780962732 @default.
• W4251686875 hasConcept C2781197716 @default.
• W4251686875 hasConcept C502942594 @default.
• W4251686875 hasConcept C526805850 @default.
• W4251686875 hasConcept C54355233 @default.
• W4251686875 hasConcept C71924100 @default.
• W4251686875 hasConcept C86803240 @default.
• W4251686875 hasConceptScore W4251686875C104317684 @default.
• W4251686875 hasConceptScore W4251686875C104451858 @default.
• W4251686875 hasConceptScore W4251686875C121608353 @default.
• W4251686875 hasConceptScore W4251686875C126322002 @default.
• W4251686875 hasConceptScore W4251686875C134935766 @default.
• W4251686875 hasConceptScore W4251686875C135763542 @default.
• W4251686875 hasConceptScore W4251686875C143998085 @default.
• W4251686875 hasConceptScore W4251686875C153209595 @default.
• W4251686875 hasConceptScore W4251686875C2776694085 @default.
• W4251686875 hasConceptScore W4251686875C2778239845 @default.
• W4251686875 hasConceptScore W4251686875C2779309665 @default.
• W4251686875 hasConceptScore W4251686875C2780962732 @default.
• W4251686875 hasConceptScore W4251686875C2781197716 @default.
• W4251686875 hasConceptScore W4251686875C502942594 @default.
• W4251686875 hasConceptScore W4251686875C526805850 @default.
• W4251686875 hasConceptScore W4251686875C54355233 @default.
• W4251686875 hasConceptScore W4251686875C71924100 @default.
• W4251686875 hasConceptScore W4251686875C86803240 @default.
• W4251686875 hasIssue "13_Supplement" @default.
• W4251686875 hasLocation W42516868751 @default.
• W4251686875 hasOpenAccess W4251686875 @default.
• W4251686875 hasPrimaryLocation W42516868751 @default.
• W4251686875 hasRelatedWork W2028622397 @default.
• W4251686875 hasRelatedWork W2109468970 @default.
• W4251686875 hasRelatedWork W2113467423 @default.
• W4251686875 hasRelatedWork W2120000242 @default.
• W4251686875 hasRelatedWork W2137234355 @default.
• W4251686875 hasRelatedWork W2154925720 @default.
• W4251686875 hasRelatedWork W2155484722 @default.
• W4251686875 hasRelatedWork W2246478070 @default.
• W4251686875 hasRelatedWork W3028670831 @default.
• W4251686875 hasRelatedWork W57764544 @default.
• W4251686875 hasVolume "79" @default.
• W4251686875 isParatext "false" @default.
• W4251686875 isRetracted "false" @default.
• W4251686875 workType "article" @default.